65y.o.< 60y.o.FractureRiskAssessmentToolq5y40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factormultidoseinitial series,then 1 doseat 2-6monthscervicalcancer3%overweight/ obesityhypertensionq3ytobaccouseaspirinHepatitisBPREVENTequationanxietyq1-2ymammogrambased on lifeexpectancy /health status≤q2y≥ 140mg/dL52y.o.40y.o.2 doses,2-6monthsapart≥ 200mg/dLovariancancerherpeszosterTyrer-CuzickmodelHepatitisCdementiaq1yhormonetherapypneumococcaltamoxifen40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorscardiovasculardiseasedepression≥20%aromataseinhibitorscommunity-dwelling,postmenopausalwomen≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors≥ 100mg/dL50y.o.dyslipidemiaq2ybreastcancerraloxifene≥6.5%75y.o.lungcancerq1ymammogram≥ 126mg/dL60y.o.≥5.7%insufficientevidenceforscreeningq15y40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorcolorectalcancerdiabetesGailmodel1 dose; 2doses (2-6monthsapart) ifimmunocompstatin40-70 y.o.,ASCVD ≥10%, lowbleeding riskwomenage 55-64 y.o.Timedup andgo test40-59 y.o.,ASCVD ≥10%, lowbleeding riskHIV65y.o.< 60y.o.FractureRiskAssessmentToolq5y40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factormultidoseinitial series,then 1 doseat 2-6monthscervicalcancer3%overweight/ obesityhypertensionq3ytobaccouseaspirinHepatitisBPREVENTequationanxietyq1-2ymammogrambased on lifeexpectancy /health status≤q2y≥ 140mg/dL52y.o.40y.o.2 doses,2-6monthsapart≥ 200mg/dLovariancancerherpeszosterTyrer-CuzickmodelHepatitisCdementiaq1yhormonetherapypneumococcaltamoxifen40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorscardiovasculardiseasedepression≥20%aromataseinhibitorscommunity-dwelling,postmenopausalwomen≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors≥ 100mg/dL50y.o.dyslipidemiaq2ybreastcancerraloxifene≥6.5%75y.o.lungcancerq1ymammogram≥ 126mg/dL60y.o.≥5.7%insufficientevidenceforscreeningq15y40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorcolorectalcancerdiabetesGailmodel1 dose; 2doses (2-6monthsapart) ifimmunocompstatin40-70 y.o.,ASCVD ≥10%, lowbleeding riskwomenage 55-64 y.o.Timedup andgo test40-59 y.o.,ASCVD ≥10%, lowbleeding riskHIV

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. 65 y.o.
  2. < 60 y.o.
  3. Fracture Risk Assessment Tool
  4. q5y
  5. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  6. multidose initial series, then 1 dose at 2-6 months
  7. cervical cancer
  8. 3%
  9. overweight / obesity
  10. hypertension
  11. q3y
  12. tobacco use
  13. aspirin
  14. Hepatitis B
  15. PREVENT equation
  16. anxiety
  17. q1-2y mammogram based on life expectancy / health status
  18. ≤ q2y
  19. ≥ 140 mg/dL
  20. 52 y.o.
  21. 40 y.o.
  22. 2 doses, 2-6 months apart
  23. ≥ 200 mg/dL
  24. ovarian cancer
  25. herpes zoster
  26. Tyrer-Cuzick model
  27. Hepatitis C
  28. dementia
  29. q1y
  30. hormone therapy
  31. pneumococcal
  32. tamoxifen
  33. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  34. cardiovascular disease
  35. depression
  36. ≥ 20%
  37. aromatase inhibitors
  38. community-dwelling, postmenopausal women
  39. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  40. ≥ 100 mg/dL
  41. 50 y.o.
  42. dyslipidemia
  43. q2y
  44. breast cancer
  45. raloxifene
  46. ≥ 6.5%
  47. 75 y.o.
  48. lung cancer
  49. q1y mammogram
  50. ≥ 126 mg/dL
  51. 60 y.o.
  52. ≥ 5.7%
  53. insufficient evidence for screening
  54. q15y
  55. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  56. colorectal cancer
  57. diabetes
  58. Gail model
  59. 1 dose; 2 doses (2-6 months apart) if immunocomp
  60. statin
  61. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  62. women age 55-64 y.o.
  63. Timed up and go test
  64. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  65. HIV